Totally agree...being current-informed while will not be a simple task. CNS and related is one a lot of menu's these days.
Keeping the correct process development speeds w/o falling off the pace probably motivated AVXL to begin to staff up w/big leaguers recently. When the WS herd starts running w/news shortly (IMO) it will too late to start connecting dots. Looks to me like AVXL is now planning to be in front of the herd but we better not fall down...tough getting up.
RSD is probably a good lead to keep working...tradeherpete [quote ]Hausman says he’s going to start an open label P2-a for Autism and Fragile X and will go for approval from the open label study when it blows the World away. It’s pre-clinical now.
No need for P-3’s!
There is a condition in semiconductor physics known as "Avalanche". IMO, when A2-73 MOA is validated we will see an avalanche. IMO, the conditions have already been verified in small controlled trials, now we will see the same process applied across multiple CNS indications. Knowing which ones and when will make informed people $$$ wealthy.
News 
Market Data 
Discover 
